grosella

Gooseberry: A Comprehensive Encyclopedic Reference

1. Identity: Botanical Names, Natural Sources, and Common Forms

1.1 The Term "Gooseberry" — Multiple Distinct Species

The common name "gooseberry" is applied to more than one botanically distinct species. In the context of dietary supplementation and traditional medicine, it primarily refers to two plants: Indian gooseberry (Phyllanthus emblica L.), also known as amla, and the European gooseberry (Ribes uva-crispa). The vast majority of the scientific and clinical literature on supplemental gooseberry concerns Phyllanthus emblica, which is the primary focus of this article. European gooseberry is covered in its own section where relevant.

1.2 Indian Gooseberry (Phyllanthus emblica / Emblica officinalis)

Phyllanthus emblica L. (synonym: Emblica officinalis) is a medium-sized deciduous tree belonging to the family Euphorbiaceae, commonly known as Indian gooseberry, emblic myrobalans, and Amla (in Hindi). It is native to the tropical and subtropical regions of the Indian subcontinent, Southeast Asia, and southern China. The plant's common and synonymous names are numerous: Emblica officinalis is also known as Emblic, Emblic myrobalan, Myrobalan, Malacca tree, and Amla (from Sanskrit amalika).

The tree is small to medium in size, reaching 1–8 metres in height. The leaves are simple, subsessile, and closely set along branchlets, light green, resembling pinnate leaves. March–April is the main blooming season. Grafted trees begin flowering in 3–4 years, while seed-grown trees may take 7–10 years.

The fruits, also known as the berries or myrobalans, are the most important part of the plant, being of dietary, culinary, and medicinal use. The tree is well suited to grow even in saline-sodic and other wasteland soil conditions, and the fruits remain in season for almost ten months.

1.3 European Gooseberry (Ribes uva-crispa)

Ribes uva-crispa, commonly known as the gooseberry or European gooseberry, is a species of flowering shrub native to Europe, northwestern Africa, and southwestern Asia. It belongs to the family Grossulariaceae, which includes currants and gooseberries. It is a deciduous shrub growing to 1.2 m in height by 1 m wide at a medium rate. The berries may be red, green, yellow, or white, hairy or smooth, with over 200 varieties recognized.

1.4 Common Forms and Preparations

Indian gooseberry (P. emblica) is available in a wide range of culinary and supplemental forms. The fruit is used to make murabbah, burfi, ladu, fresh juice, pickles, chutneys, and curries in India. In supplemental contexts, amla supplements contain powder or extract made from amla fruit. These may be standardized to levels of compounds such as phenols or, more specifically, tannins or gallic acid equivalents. Amla is also sold as fresh fruit, frozen fruit, fruit juice, and syrup.

Several proprietary standardized extracts have been developed for the supplement market. The Saberry extract (by Sabinsa) is standardized to 10% beta-glucogallin and hydrolyzable tannins, while the CAPROS extract (by Natreon) is standardized to 60% low-molecular-weight hydrolyzable tannins, and has been used in cardiovascular studies.

Amla is also a core ingredient in classical Ayurvedic multi-herb formulations. It is a main component of the popular multicomponent Ayurvedic formulations Triphala churna and Chyawanprash. Chyawanprash consists of Amla/Amalaki (Phyllanthus emblica/Indian gooseberry) pulp as a base, and this is considered to be the most effective Rasayana for sustaining homeostasis. Chyawanprash is formulated by processing around 50 medicinal herbs and their extracts, including the prime ingredient Amla (Indian gooseberry).

Amla powder is made by sun-drying or low-heat drying fresh amla fruit and then finely milling it into a pale green powder. What makes this preparation unique is its exceptionally high vitamin C content naturally stabilized by tannins and flavonoids.

2. Traditional and Historical Use

2.1 Ayurveda (Indian Traditional Medicine)

Amla has a long history not just in medicine but also in ancient Indian scriptures and cultural traditions. In classical Ayurvedic texts, such as the Charaka Samhita — a work on Indian medicine dating back more than two millennia — amla (Sanskrit: amalaki) is described as an important herb and is praised for its nourishing and longevity-promoting qualities.

The first mentions of Amla appear in Charaka Samhita (circa 1st–2nd century CE) under the name "Amalaki," lauded as a supreme Rasayana. Sushruta Samhita also highlights Amalaki's capacity to balance all three doshas, but especially to pacify Pitta. In Charaka Samhita Sutrasthana 27/245, it is described as the best among all Rasayana herbs for promoting health and longevity, while Sushruta Samhita Sutrasthana 46/333 highlights its role in balancing the three doshas, particularly pacifying Pitta.

Amla is one of three fruits that compose Triphala — the foundational Ayurvedic formulation used across multiple therapeutic applications — alongside haritaki and bibhitaki. In the classical Ayurvedic system, amla is described as possessing five of the six tastes — sour, sweet, bitter, pungent, and astringent — which in Ayurvedic pharmacology indicates broad therapeutic applicability across multiple systems.

Its actions are documented as Chakshushya (beneficial to the eyes), Keshya (beneficial to hair), Varnya (brightening to the complexion), and Rasayana (regenerative and restorative).

Almost all parts of the tree — root, bark, leaf, flower, fruit, and seed — are utilized in Ayurvedic and Unani medicinal formulations to improve the overall digestive process, decrease fever, act as a blood purifier, relieve asthma and cough, improve heart health, etc.

2.2 Unani, Siddha, and Other South/Southeast Asian Systems

The Indian gooseberry has a history of use in traditional medical systems including Ayurveda, Unani, and Siddha. In these traditions, the fruit is commonly described as a rasayana, a type of substance associated with rejuvenation and long-term health maintenance. The fruits are indispensable in the various folk systems of medicine in Southeast Asia, and are used to treat ailments including diabetes, cough, asthma, bronchitis, cephalalgia, ophthalmopathy, skin diseases, hemorrhoids, nervine debility, leprosy, inflammation, dyspepsia, colic, flatulence, hyperacidity, peptic ulcer, jaundice, diarrhea, dysentery, hemorrhage, and cardiac disorders.

2.3 Traditional Persian Medicine

Amla (Phyllanthus emblica) fruit has been emphasized as a hair tonic in Traditional Persian Medicine (TPM) and recommended for hair loss both orally and topically.

2.4 European Gooseberry (Ribes uva-crispa) Traditional Use

The fruit of Ribes uva-crispa is laxative. Stewed unripe gooseberries are used as a spring tonic to cleanse the system. The leaves have been used in the treatment of gravel. The leaves contain tannin and have been used as an astringent to treat dysentery and wounds. The juice was formerly said to "cure all inflammations."

2.5 Traditional Preparations

The Indian gooseberry has traditionally been consumed — in its fresh or dried forms or as an ingredient in simple preparations — as a dietary tonic intended to support digestion, regulate bowel function, and promote general well-being. Classical preparations include use of the root, bark, leaf, flower, fruit, and seed in Ayurvedic and Unani medicinal formulations.

3. Key Constituents and Active Compounds

3.1 Vitamin C

P. emblica fruit is the second richest known source of vitamin C, as well as having high levels of tannins, alkaloids, polyphenols, vitamins, and minerals. Vitamin C, a potent antioxidant, has been reported to be present in fresh amla fruit in concentrations ranging from 252 mg to 400 mg per 100 g of fruit. Notably, unlike many fruits where vitamin C degrades quickly, amla contains natural stabilizing compounds that help preserve its antioxidant potency.

3.2 Hydrolyzable Tannins and Ellagitannins

Ellagitannins, such as emblicanin A and B, corilagin, chebulagic acid, chebulinic acid, geraniin, isocorilagin, pedunculagin, phyllanemblinins A–F, and punigluconin, are potent antioxidants that can be found in amla fruit. This tree contains major secondary metabolites — emblicanin-A and emblicanin-B — and is also an affluent source of vitamin C. Additionally, tannins, gallic acid, pyrogallol, and pectin are present in significant amounts.

3.3 Phenolic Acids and Flavonoids

P. emblica contains several biologically active antioxidant polyphenols, including gallic acid, pyrogallol, emblicanin A and B, pentagalloylglucose, and ellagic acid. Emblic also contains punicafolin and phyllanemblinin A, phyllanemblin, and other polyphenols such as flavonoids, kaempferol, ellagic acid, and gallic acid.

Gallic acid is particularly notable, as its presence (over 1.2%) is used as a quality standard for Amla (P. emblica) in traditional Chinese medicine.

3.4 Lignans and Other Constituents

Other notable phytochemicals include lignans such as phyllanthin and hypophyllanthin, primarily in the leaves and fruits, and phyllemblic acid, which occurs at approximately 6.3% in the fruit.

3.5 Nutritional Constituents

The fruit is a reservoir of various nutraceuticals like calcium, vitamin C, lysine, minerals, methionine, nicotinic acid, phosphorus, riboflavin, and tryptophan. Amla is also enriched with essential nutrients including phosphorus, iron, sodium, vitamin A, fibre, and magnesium, further bolstering its therapeutic value.

3.6 European Gooseberry (Ribes uva-crispa) Constituents

The fruit of Ribes uva-crispa contains significant amounts of phenolic compounds, including quercetin derivatives, flavonol glycosides, and hydroxycinnamic acid derivatives. The berries' total phenolic content ranges from 3.52 to 30.77 grams per kilogram, with flavonoids being the most abundant phenolic substances at levels of 345.0 to 3726.5 milligrams per kilogram. These vibrant berries contain notable concentrations of anthocyanins, particularly cyanidin-3-glucoside and peonidin-3-glucoside, which are responsible for their red coloration. Historical botanical sources list citric acid, pectuse (pectin), sugar, and mineral matter among constituents of European gooseberry, with pectuse causing the fruit to be excellent for jellies.

4. Established Mechanisms of Action

4.1 Free Radical Scavenging and Antioxidant Defense

Bioactive compounds such as vitamin C, polyphenols, and tannins in amla effectively neutralize reactive oxygen species (ROS), including superoxide anions, hydroxyl free radicals, nitric oxide (NO), and malondialdehyde (MDA). These constituents also support endogenous antioxidant defenses, including glutathione (GSH), catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase.

Research has shown that all major polyphenolic compounds of P. emblica scavenge DPPH radicals; emblicanin B was found to be the best scavenger, and efficiency decreased in the order: emblicanin B > emblicanin A > gallic acid > ellagic acid > ascorbic acid.

4.2 Anti-inflammatory Mechanisms

Amla's anti-inflammatory power comes from its ability to inhibit several inflammation-triggering enzymes, including COX-1, COX-2, and 5-LOX. By reducing these enzymes, it lowers the production of molecules that cause swelling and pain. Amla fruit extract has been shown to reduce the production of key inflammatory substances — NO, Tumour Necrosis Factor-alpha (TNF-α), Interleukin-1 beta (IL-1β), and Interleukin-6 (IL-6). The compounds gallic acid and fisetin have been shown to be responsible for this activity.

At the cellular level, a fruit extract powder of Amla was shown to scavenge reactive oxygen species produced in RAW246.7 macrophages upon lipopolysaccharide stimulation, as well as suppressing NF-κB, COX-2, and iNOS expression. Cumulatively, these studies point to constituents of Amla modulating inflammatory cytokines such as IL-6, NF-κB, enzymes such as superoxide dismutase, and signalling pathways involved in oxidative stress as well as the cell cycle.

4.3 Glucose Metabolism Mechanisms

Emblica extract treatment increased the membrane expression levels of skeletal muscular GLUT4, and also reduced hepatic mRNA levels of glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase, thereby inhibiting hepatic gluconeogenesis, resulting in a net glucose-lowering effect. Emblica extract increased the expression levels of p-AMPK/t-AMPK in both skeletal muscle and liver tissue, and enhanced expression levels of fatty acid oxidation enzymes, including peroxisome proliferator-activated receptor α (PPARα), while reducing expression levels of lipogenic genes including fatty acid synthase.

4.4 Lipid-Lowering Mechanisms

In vitro and animal studies have shown that the flavonoids from Emblica officinalis effectively reduce lipid levels in blood serum and tissues. Polyphenol-rich extracts of P. emblica have reduced metabolic changes caused by excessive fructose consumption, including alteration of triglyceride and total cholesterol levels and sterol regulatory element-binding protein 1 (SREBP-1) expression, in animal models.

4.5 Anti-thrombotic and Antiplatelet Activity

Amla compounds possess anti-thrombosis properties to promote vascular health by improving blood fluidity, with anti-coagulant and antiplatelet activity. Amla also supports natural immunity and digestive functions.

4.6 Skin-Related Mechanisms

Owing to its high vitamin C content together with high polyphenol content, P. emblica extract exerts a strong inhibitory effect on tyrosinase enzyme, along with antioxidation, antibacterial, and anti-inflammatory effects. Regarding anti-aging potential, matrix metalloproteinases (MMP)-2 and MMP-9 — degenerative enzymes of skin collagen and elastin — can be attenuated by the extract.

4.7 Hair Growth Mechanisms

In vivo studies have demonstrated hair growth-enhancing activities of Amla because it contains compounds that effectively increase the size of hair follicles and prolong the anagen phase.

5. Scientific Evidence by Area of Use

5.1 Cardiometabolic Health — Lipid Profile

Evidence strength: Moderate (several RCTs, but relatively small scale, high variability, and moderate duration)

A multicenter, randomized, double-blind, placebo-controlled clinical trial investigated the effects of amla extract on dyslipidemia. A total of 98 dyslipidemic patients were enrolled and divided into amla and placebo groups. Amla extract (500 mg) or a matching placebo capsule was administered twice daily for 12 weeks to respective groups. Efficacy was assessed by analyzing lipid profile, along with apolipoprotein B, apolipoprotein A1, Coenzyme Q10, high-sensitive C-reactive protein, fasting blood sugar, homocysteine, and thyroid stimulating hormone.

In 12 weeks, major lipids — total cholesterol (TC) (p=0.0003), triglyceride (TG) (p=0.0003), low-density lipoprotein cholesterol (LDL-C) (p=0.0064), and very low-density lipoprotein cholesterol (VLDL-C) (p=0.0001) — were significantly lower in the amla group compared to placebo. The amla extract showed significant potential in reducing TC and TG levels as well as lipid ratios, AIP and apoB/apo A-I in dyslipidemic persons, and thus has scope to treat general as well as diabetic dyslipidemia. Notably, cholesterol reduction was achieved without concomitant reduction of CoQ10, in contrast to what is observed with statins.

In a study in normal and diabetic volunteers, significant decreases were observed in total cholesterol and triglycerides, and increases were observed in high-density lipoprotein-cholesterol (HDL-C) in normal and diabetic volunteers receiving 2 or 3 g of Phyllanthus emblica powder per day.

A 2023 systematic review and meta-analysis of available RCTs noted that the high variability among completed human trials limits conclusive support for supplementation, even though amla supplementation shows promise for improving metabolic parameters in adults. Populations included in the meta-analysis were generally aged 40–58 years with an average BMI of 25.5, and the length of intervention ranged from 3 to 12 weeks.

5.2 Cardiometabolic Health — Blood Sugar and Diabetes

Evidence strength: Preliminary to moderate (small RCTs, mechanistic animal data, high variability in study design)

Several clinical trials have investigated amla for blood sugar outcomes. Small and preliminary studies suggest that amla may be helpful in diabetes, cholesterol lowering, high blood pressure, gastroesophageal reflux disease (GERD), and colds and flu, but more conclusive research is needed.

One study on type 2 diabetes patients and normal subjects used 1 to 3 g of powdered, dried fruit consumed daily in 30 mL of water for 21 days. Another trial used amla 300 mg tablets (each containing 50% amla extract and 50% dextrin) three times per day.

In patients with metabolic syndrome and confirmed endothelial dysfunction, a significant decrease was reported in high-sensitivity C-reactive protein levels (p<0.001) compared with baseline following 12 weeks of supplementation with a standardized P. emblica extract (CAPROS) 500 mg twice daily. Similar improvements in hs-CRP were observed with CAPROS 250 mg and 500 mg given for 12 weeks, with the 500 mg dose performing significantly better than the lower dose (p<0.05) in another double-blind, randomized, placebo-controlled study that enrolled 59 patients with metabolic syndrome and confirmed endothelial dysfunction.

Also, an aqueous extract of fruits from Phyllanthus emblica given twice daily at 500 mg and 250 mg dosages was found to affect endothelial dysfunction, systemic inflammation, oxidative stress, and lipid profile in subjects with metabolic syndrome. The aqueous extract significantly improved endothelial function, systemic inflammation, oxidative stress, and lipid profile at both tested dosages, but particularly at 500 mg twice daily.

5.3 Antioxidant and Anti-inflammatory Activity in Humans

Evidence strength: Moderate (RCT data for oxidative biomarkers; much of the mechanistic evidence remains in vitro or animal)

A randomized, double-blind, crossover, placebo-controlled study in healthy human subjects assessed amla's antioxidant activity. Eligible healthy adult subjects (n=15) were randomized to receive either amla or placebo (500 mg per day) during an 18-week study. Efficacy parameters evaluated were vascular function, blood hematology, oxidative and inflammatory biomarkers, glucose and lipid profiles, urinalysis, and liver hepatotoxicity. Amla intake showed significant improvements in the primary efficacy parameter of blood fluidity. There were also improvements in the secondary endpoints including lowering of von Willebrand factor (vWF), reduced 8-hydroxy-2'-deoxyguanosine (8-OHdG), as well as thrombin (TM) biomarkers of oxidative stress, along with a significant improvement in HDL-cholesterol and lowering of LDL-cholesterol levels. The small sample size (n=15) limits the generalizability of these findings.

An aqueous extract of P. emblica (100 μg/ml) significantly modulated the basal levels of oxidative markers and enhanced antioxidant defenses in HepG2 liver cells; another extract scavenged superoxide and hydroxyl radicals and decreased the level of lipid hydroperoxide and reactive oxygen species in HepG2, Dalton's Lymphoma Ascites (DLA), and CeHa cells. These findings are from cell-based (in vitro) models and cannot be directly extrapolated to human outcomes.

5.4 Digestive Health and Gastroesophageal Reflux Disease (GERD)

Evidence strength: Preliminary (single RCT, small scale)

One double-blind, randomized, placebo-controlled trial examined amla's effects on GERD. The 4-week study in 68 people with gastroesophageal reflux disease investigated the effects of taking amla fruit extract. Researchers observed that the amla fruit group experienced greater reductions in the frequency and severity of heartburn and vomiting than those in the placebo group. The dosing used was described as follows: participants took two 500 mg tablets of amla fruit powder twice daily after meals (total daily dose of 2,000 mg) or placebo for 4 weeks. The daily consumption of amla extract (500 mg/tablet, twice a day) reduced the severity and frequency of regurgitation and heartburn in comparison to the placebo group. These findings support protection of organs involved in digestion with amla phytochemicals (especially polyphenols). Though this study is promising, more research is needed to fully understand the effects of Indian gooseberry supplements on heartburn and GERD.

5.5 Cardiovascular Risk Markers

Evidence strength: Preliminary (one uncontrolled study, one small RCT)

A study in Ohio enrolled overweight or obese individuals who took 500 mg of amla extract (CAPROS by Natreon, standardized to 60% low-molecular-weight hydrolyzable tannins) twice daily (1,000 mg total/day) for 12 weeks. Platelet aggregation induced by collagen was reduced, suggesting an antiplatelet effect that could lower blood clot risk. The lack of a control group in this study limits the significance of these findings.

Amla may reduce blood clotting through its antiplatelet effects. The CAPROS study demonstrated that amla extract reduced collagen-induced platelet aggregation in overweight/obese individuals. The combined anti-inflammatory, anti-thrombosis, anti-coagulant, and anti-platelet activities of amla make it an attractive target for the prevention of a variety of vascular disorders.

5.6 Skin Health and Anti-aging

Evidence strength: Preliminary (small RCTs for topical use; mostly in vitro data for oral use)

A randomized, double-blind, placebo-controlled study examined topical use of amla branch extract. The study was performed in 20 volunteers for 84 consecutive days. Amla branch extract consisted of a variety of phenolic acids, mainly sinapic and ferulic acids. The extract exhibited potent antioxidant and tyrosinase inhibitory activities in vitro, and melanin suppression through inhibition of tyrosinase and tyrosinase-related protein-2 activities, along with potent matrix metalloproteinase-2 inhibition in cellular assays at 0.1 mg/mL. A topical gel containing 0.1% extract was a stable and safe formulation. The clinical study demonstrated superior anti-skin aging efficacy, including lightening of skin color, enhanced skin elasticity and hydration, and skin wrinkle reduction.

A systematic review of published studies on Triphala (of which amla is a constituent) and dermatology noted that studies explored anti-aging properties (n=22), antioxidant activity (n=14), protection against ultraviolet radiation (n=8), anti-cancer properties (n=3), and wound healing (n=9), in addition to the treatment of conditions including hair loss (n=8) and other dermatological conditions. However, many of these studies were conducted on the Triphala combination rather than amla in isolation, limiting attribution to any single ingredient.

5.7 Hair Health and Androgenetic Alopecia

Evidence strength: Preliminary (single small RCT)

A triple-blind, randomized, controlled clinical trial evaluated the effect of oral amla syrup on female androgenetic alopecia (FAGA). Sixty women with FAGA were randomly assigned into two groups of thirty. The intervention group received ten cc Amla syrup thrice a day for 12 weeks. The second group received a placebo with the same dose and duration. Hair growth parameters were analyzed using TrichoScan before and after 12 weeks of intervention. The results demonstrated that Amla syrup could help treat androgenic hair loss in women and increase the anagen phase. Further studies are needed to evaluate this potential treatment for FAGA. ConsumerLab notes that amla has not been conclusively shown to help with hair growth, and that evidence for benefits related to liver or kidney function, Alzheimer's disease, macular degeneration, aging skin, and cancer remains limited.

5.8 European Gooseberry (Ribes uva-crispa) — Evidence

Evidence strength: Largely preliminary (in vitro and limited human data)

Research indicates that European gooseberry exhibits notable α-amylase and α-glucosidase inhibitory activities, which help regulate the breakdown of carbohydrates and support healthy glucose absorption in the digestive system. These compounds work by inhibiting α-amylase and α-glucosidase enzymes, which are responsible for breaking down starches into simple sugars, thereby helping to slow glucose absorption and reduce post-meal blood sugar spikes. This evidence is primarily in vitro and has not yet been confirmed in controlled human clinical trials.

6. Body Systems and Health Areas

The rich composition of polyphenol and vitamin C imparts an important antioxidant activity along with important in vivo effects that include improved antioxidant status and activity of the endogenous antioxidant defense system. Other potential health benefits include anti-hyperlipidemia and antidiabetic activities as well as anticancer, anti-inflammatory, digestive tract, and neurological protective activities.

• Cardiovascular system: Effects on lipid profile (TC, TG, LDL-C, HDL-C), platelet aggregation, vascular endothelial function, and blood fluidity have been the subject of several RCTs.
• Metabolic / endocrine system: Blood glucose regulation, improvement in insulin sensitivity, and effects on HbA1c markers have been investigated in both preclinical and clinical settings.
• Gastrointestinal system: Traditional use as a digestive tonic, plus a clinical trial in GERD, and in vitro gastroprotective evidence.
• Immune system: Amla is said to have immune-boosting efficiency against multiple diseases.
• Integumentary system (skin and hair): Anti-aging, tyrosinase inhibition, collagen protection, and androgenetic alopecia explored in small clinical studies.
• Hepatic system: Amla contains high concentrations of antioxidants — ascorbic acid, gallic acid, and phenolic compounds — suggesting antioxidant activity that may be beneficial for prevention of age-related renal disease. Amla extracts are reported to have the ability to modulate basal oxidative markers and enhance endogenous antioxidant defenses in hepatocyte cell lines (HepG2). Evidence is limited to in vitro models.
• Neurological system: There is limited evidence to support longevity-promoting effects of Emblica officinalis, but preliminary evidence suggests potent antioxidant activity. In brain cells, amla has high antioxidant activity.

7. Dosage Forms and Dosages Reported in Studies

Doses of 1 to 3 grams daily of amla fruit powder or amla fruit extract have been used in studies for blood sugar control, while 500 mg daily has been used for cholesterol lowering.

• Dyslipidemia (multicenter RCT): Amla extract (500 mg) or a matching placebo capsule was administered twice daily for 12 weeks. The extract used was standardized to 35% galloelagi tannins.
• Metabolic syndrome / endothelial dysfunction (RCT): CAPROS 500 mg twice daily, or CAPROS 250 mg and 500 mg for 12 weeks.
• GERD (RCT): Two 500 mg tablets of amla fruit powder twice daily after meals (total daily dose of 2,000 mg) for 4 weeks.
• Healthy subjects (crossover RCT): 500 mg per day for 18 weeks.
• Blood glucose/lipid (diabetic subjects): 2 or 3 g of Phyllanthus emblica powder per day. In another format, 1 to 3 g of powdered, dried fruit consumed daily in 30 mL of water for 21 days; or amla 300 mg tablets (each containing 50% amla extract and 50% dextrin) 3 times per day.
• Female androgenetic alopecia (RCT): Ten cc Amla syrup thrice a day for 12 weeks.
• Anti-skin aging (RCT, topical): Topical gel containing 0.1% extract applied for 84 consecutive days.

A significant issue with amla supplements is the lack of a unified standardization approach. Different products are standardized to different marker compounds: phenols or polyphenols, tannins or gallic acid equivalents, or specific compounds such as beta-glucogallin.

Independent tests of popular amla supplements have found that most did not meet quality standards because they lacked the full chemical profile of amla and/or contained less than expected total amounts of phenolic compounds. Some contained slightly more lead than others, although none exceeded strict contamination limits for lead or other heavy metals (arsenic, cadmium, and mercury).

8. Safety Considerations and Drug Interactions

Data support the benefit of emblica supplementation in dyslipidemic patients as well as antioxidant and anti-inflammatory activity. There is limited robust clinical evidence to support the use of emblica for any other indication.

8.1 Anticoagulant and Antiplatelet Interactions

Those on anticoagulants, like warfarin, should be careful. Indian gooseberry may affect blood clotting and raise bleeding risks. This is supported by mechanistic evidence: findings of an in vitro study revealed that the methanolic extract of amla contains significant antioxidant, anti-inflammatory, and anticoagulation activity. Amla may reduce blood clotting through its antiplatelet effects. The CAPROS study demonstrated that amla extract reduced collagen-induced platelet aggregation in overweight/obese individuals.

8.2 Blood Glucose-Lowering Medications

Amla may lower blood sugar. This can interfere with diabetes medications and cause hypoglycemia. Individuals using antidiabetic drugs should monitor blood glucose levels when using amla concurrently.

8.3 Diuretic and Blood Pressure Medications

Amla's diuretic effects may interact with some medications, including those for lowering blood pressure, as they have a similar effect.

8.4 Pregnancy and Lactation

Pregnant or breastfeeding women should avoid Amla unless advised otherwise by a healthcare provider. There is little research on its safety during these periods.

8.5 General Tolerability

In the multicenter RCT on dyslipidemia, amla at 500 mg twice daily was assessed for safety over 12 weeks; cholesterol reduction was achieved without concomitant reduction of CoQ10, in contrast to what is observed with statins, suggesting a potentially more favorable safety profile than statins in that respect. In the healthy volunteer crossover study, amla at 500 mg/day for 18 weeks was evaluated for urinalysis and liver hepatotoxicity markers, with no adverse findings reported in the published results.

8.6 Heavy Metal Contamination (Product Quality Concern)

Some amla supplement products were found to contain slightly more lead than others, although none exceeded strict contamination limits for lead or other heavy metals (arsenic, cadmium, and mercury). This is a practical concern relevant to product sourcing and quality control, not an intrinsic toxicological property of the plant itself.

8.7 Gastrointestinal Effects

Too much amla can cause side effects like digestive issues or allergies. The laxative property of gooseberry (documented for both P. emblica and Ribes uva-crispa) may be relevant at higher doses.

References

• ScienceDirect Topics: Phyllanthus emblica — Overview
• Wikipedia: Phyllanthus emblica
• ScienceDirect Topics: Emblica officinalis — Overview
• PMC: Advances in biotechnology of Emblica officinalis Gaertn. syn. Phyllanthus emblica L.: a nutraceuticals-rich fruit tree with multifaceted ethnomedicinal uses
• Wikipedia: Ribes uva-crispa (European Gooseberry)
• Encyclopædia Britannica: Indian Gooseberry (Amla)
• PMC: Molecular Mechanisms of Cancer Prevention by Gooseberry (Phyllanthus emblica)
• PMC: Functional and Nutraceutical Significance of Amla (Phyllanthus emblica L.): A Review
• PMC / BMC Complementary and Alternative Medicine: A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia
• PubMed: The impact of Emblica Officinalis (Amla) on lipid profile, glucose, and C-reactive protein: A systematic review and meta-analysis of randomized controlled trials
• PMC: Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study
• PMC: Antidiabetic and antihyperlipidemic activities of Phyllanthus emblica L. extract in vitro and the regulation of Akt phosphorylation, gluconeogenesis, and PPAR-α in streptozotocin-induced diabetic mice
• PMC: Chyawanprash: A Traditional Indian Bioactive Health Supplement
• PubMed: Phyllanthus emblica L. (amla) branch: A safe and effective ingredient against skin aging
• PubMed: The effect of an oral product containing Amla fruit (Phyllanthus emblica L.) on female androgenetic alopecia: A randomized controlled trial
• ScienceDirect: Phyllanthus emblica (Amla) methanolic extract regulates multiple checkpoints in 15-lipoxygenase mediated inflammopathies
• Journal of Integrative Dermatology: Triphala in Dermatology — A Systematic Review
• ConsumerLab: Amla (Indian Gooseberry) Health Benefits and Safety
• Drugs.com Natural Product Database: Emblica Uses, Benefits & Dosage
• Dr. Brad Stanfield: Amla (Indian Gooseberry) — Benefits, Forms, Dosing, and Side Effects
• PMC: Recent Insights into the Morphological, Nutritional and Phytochemical Properties of Indian Gooseberry (Phyllanthus emblica) for the Development of Functional Foods
• bioRxiv: Dietary Phyllanthus emblica L. (Indian gooseberry, Amla) improves fecundity and resistance to oxidative stress in a Drosophila melanogaster model
• Botanical.com — A Modern Herbal: Gooseberry